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Summary
Bone remodelling is an active and dynamic process that relies
on the correct balance between bone resorption by osteoclasts
and bone deposition by osteoblasts. Moreover, these two func-
tions must be tightly coupled not only quantitatively, but also in
time and space. When the coupling is lost, the correct bone
mass could be compromised, leading to several skeletal
pathologies. Indeed, bone loss and osteoporosis are the result
of an increased osteoclast function and/or a reduced osteoblast
activity. In contrast, other pathologies are related to osteoclast
failure to resorbe bone, such as osteopetrosis, a rare genetic
disorder characterized by an increased bone mass and also
linked to an impairment of bone marrow functions. Starting
from these assumptions, it is necessary to more deeply under-
stand the molecular mechanisms regulating bone cell func-
tions. Indeed, recent studies evidenced a complex interplay be-
tween the immune and skeletal systems, which share several
regulatory molecules including cytokines, receptors and tran-
scription factors. These data allowed to more deeply under-
stand the mechanisms underlying bone mass regulation and
could open new avenue to identify target molecules for alteran-
tive therapies more efficacious against bone diseases.
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The bone remodelling process
Bone is a dynamic tissue, subjected to a continuous renewing
during the life of each individual by the process of bone remod-
elling (1, 2). This physiological process is necessary:
– to allow the substitution of primary bone, the infantile bone,
with secondary bone which is more mechanically competent;
– to remove ischemic or microfractured bone;
– to guarantee a correct calcium homeostasis.
Bone remodelling relies on the correct function of two princi-
pal cells of the bone tissue: the osteoclasts, multinucleated
cells that destroy the bone matrix, and the osteoblasts, hav-
ing osteogenic functions. The osteocytes, another important
cell type arising from the osteoblasts, are also involved in the
remodelling process as they have a mechano-sensorial func-
tion (3).
A correct balance between bone resorption and osteogenic
functions is mandatory to maintain a constant bone mass (1,
2).
As summarized in Figure 1, bone remodelling is accomplished
according to the following phases.
Activation phase. Different inputs, such as a micro-fracture, an
alteration of mechanical loading sensed by the osteocytes or
some factors released in the bone microenvironment, including
insulin growth factor-I (IGFI), tumour necrosis factor-α (TNF-α),
parathyroid hormone (PTH) and interleukin-6 (IL-6), activate
the lining cells which are quiescent osteoblasts. As a conse-
quence, lining cells, increase their own surface expression of
RANKL (Receptor Activator of Nuclear κB Ligand), which in
turn interacts with its receptor RANK (Receptor Activator of Nu-
clear κB), expressed by pre-osteoclasts. RANKL/ RANK inter-
action triggers pre-osteoclasts fusion and differentiation toward
multinucleated osteoclasts.
Resorption phase. Once differentiated, osteoclasts polarize,
adhere to the bone surface and begin to dissolve bone. This
function requires two steps: i) acidification of the bone matrix to
dissolve the inorganic component, and ii) release of lysosomial
enzymes, such as cathepins K, and of MMP9, both in charge
for the degradation of the organic component of bone. Once
accomplished their function, osteoclasts undergo to apoptosis.
This is a physiological consequence needed to avoid an exces-
sive bone resorption.
Reverse phase. The reverse cells, whose role has not been yet
completely clarified, perform this phase. Indeed, it is known
that they are macrophage-like cells with a likely function of re-
moval of debris produced during matrix degradation.
Formation phase. Bone matrix resorption leads to the release
of several growth factors herein stored, including bone morpho-
genetic proteins (BMPs), fibroblast growth factors (FGFs) and
transforming growth factor β (TGF β), which are likely responsi-
ble for the recruitment of the osteoblasts in the reabsorbed
area. Once recruited, osteoblasts produce the new bone ma-
trix, initially not calcified (osteoid) and then they promote its
mineralization, thus completing the bone remodelling process. 
Unbalance between the resorption and formation phases mirror
an incorrect bone remodelling, which in turn affects the bone
mass, eventually leading to a pathological condition.
The bone remodelling players
To more deeply understand the causes of an altered bone re-
modelling it is necessary to know the mechanisms underlying
the biology and function of bone cells. As already mentioned,
two principal bone cells actively attend the bone remodelling,
that is the osteoblasts and the osteoclasts, and an overview of
their regulation and function will be done.
Regulation and function of osteoblasts
Osteoblastogenesis
Osteoblasts arise from mesenchymal stem cells (MSCs), which
are pluripotent cells that following a specific program of gene
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Figure 1 - Schematic representation of the bone remodelling process. Bone remodelling starts when different inputs led to activation of lining cells,
which increase surface expression of RANKL. RANKL interacts with its receptor RANK (Receptor Activator of Nuclear κB) thus triggering osteoclast
differentiation (Activation phase). Osteoclasts resorbe bone (Resorption Phase) thus allowing the release of factors usually stored in the bone matrix
(BMPs, TGFβ, FGFs) that recruit osteoblasts in the reabsorbed area. Once recruited, osteoblasts produce the new bone matrix, and promote its min-
eralization (Formation phase), thus completing the bone remodelling process (Pre-OCLs = pre-osteoclasts; OCL = osteoclast; OBLs = osteoblasts).
expression may give rise to different tissue specific cells includ-
ing osteoblasts, chondrocytes, fibroblasts, myocytes and
adipocytes (4, 5).
The initial step of osteoblastogenesis is the commitment of
MSCs towards an osteo/chondro-progenitor (Figure 2). As de-
scribed in more detail later, the Wingless-int (Wnt) pathway
and the BMPs play a key role in these early events. Indeed, a
recent report (6) showed that Wnt10b not only shifts the com-
mitment towards an osteo/chondro progenitor, but also inhibits
preadipocyte commitment (Figure 2). This is due to the sup-
pression of the adipogenic transcription factors CCAAT en-
hancer binding protein α (C/EBPα) and peroxisome prolifera-
tor-activated receptor γ (PPARγ) along with to an induction of
transcription factors Runt-related transcription factor 2 (Runx2),
distal-less homeobox 5 (Dlx5), and Osterix (Osx), the latter
downstream of Runx2 (7). Conversely, high levels of Wnt sig-
nalling with the presence of Runx2 promote osteoblastogene-
sis at the expense of chondrocyte differentiation (8). Commit-
ted pre-osteoblasts are identifiable as they express Alkaline
Phosphatase (ALP), one of the earliest markers of osteoblast
phenotype. As the pre-osteoblasts cease to proliferate, a key
signalling event occurs for development of the large cuboidal
differentiated osteoblasts. The active osteoblast is highly en-
riched in ALP and secrete bone matrix proteins such as colla-
gen I and several non-collagenous proteins including osteocal-
cin, osteopontin, osteonectin and bone sialoprotein II (BSPII).
As a rule, ALP and the type 1 parathyroid receptor (PTH1R)
are early markers of osteoblast progenitors that increase as os-
teoblasts mature and deposit matrix, but decline again as os-
teoblasts become osteocytes, whereas osteocalcin is a late
marker that is up-regulated only in post-proliferative mature os-
teoblasts associated with mineralized osteoid (9). 
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Figure 2 - Schematic picture of the osteoblastogenesis process. Osteoblasts (OBL) arise from mesenchymal stem cells (MSC) which under proper
stimuli are committed toward an osteo/chondro-progenitor (osteo/chondro-prog.), followed by an osteoprogenitor cell (Osteo-prog.), a pre-osteoblast
(pre-OBL) expressing alkaline phosphatase (ALP) and an active, mature osteoblast which secretes bone matrix proteins. 
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a) Osteoblast regulation
A correct osteoblastogenesis relies on the activation of a com-
plex network of pathways whose alteration causes several
skeletal pathologies. In the next paragraphs we will focus on
some of the principal mechanisms of osteoblast regulation.
Runt-related transcription factor 2 (Runx2). This transcription
factor plays a key role in skeletal development as it is a master
gene for osteoblast differentiation, driving the early steps of
mesenchymal commitment toward the pre-osteoblast pheno-
type (10-12). Indeed, in Runx2 null mice lack of osteoblast dif-
ferentiation results in the absence of bone formation, and chon-
drocytes of cartilages templates fail to undergo hypertrophy,
while overexpression of a dominant-negative form of Runx2 in
osteoblasts inhibits bone formation (13). Interestingly, Runx2
overexpression also leads to osteopenia, thus indicating that
this factor at inappropriately high levels can inhibit the process
of osteoblast maturation (14). In humans, haploinsufficiency of
Runx2 causes cleidocranial dysplasia (CCD), an autosomal-
dominant disease with abnormalities in bones formed by in-
tramembranous ossification (15, 16). 
Among the molecules able to regulate Runx2, BMPs, TGF β,
PTH and FGFs promote its activation, while the transcription
factor Twist is a negative regulator (17).
Osterix (Osx). This factor is downstream of Runx2 and, like the
latter, is necessary for skeletal formation (18). To accomplish
this function Osx needs to interact with activated NFAT2 (19). 
Wnt/β-catenin signalling. Recent reports evidenced a pivotal
role of this pathway in bone biology (20, 21). Indeed, the great
interest for Wnt signalling in bone field came after the discov-
ery that loss and gain-of-function mutations in the Low-density
lipoprotein receptor-related protein 5 (LRP5), a putative Wnt
co-receptor, led to the osteoporosis-pseudoglioma syndrome
(22) and to high bone mass (HBM) (23, 24) respectively in hu-
mans. LRP5 is a transmembrane receptor, which interacts with
the frizzled receptor. Binding of Wnt to frizzled and LRP5/6 re-
ceptor complex triggers a signal involving the proteins Di-
sheveled (Dvl), Axin and Frat-1, thus inhibiting the activity of
the Glycogen synthase kinase 3β (GSK3β) (25). This inhibition
prevents β-catenin phosphorylation. Indeed, hypophosporylat-
ed β-catenin is more stable, thus accumulating in the cyto-
plasm. Upon reaching a certain concentration level, β-catenin
translocates to the nucleus where it interacts with the Tcf/Lef
family of transcription factors to regulate the expression of Wnt
target genes. In contrast, in the absence of Wnt, GSK3β phos-
phorylates β-catenin, thus targeting the protein to proteasome
ubiquitination (26, 27).
Wnt signalling is subjected to a fine tune regulation by several
factors. Among them, the members of the secreted frizzled-re-
lated protein (sFRP) family and Wnt inhibitory factor 1 (Wif-1).
These molecules are soluble decoy frizzled receptors that pre-
vent interactions between Wnt and frizzled. A second group of
inhibitors includes dickkopf (Dkk) and sclerostin (Sost) pro-
teins, which bind to LRP5/6 receptors. Moreover, interaction of
the Dkk/LRP complex with kremen internalises the complex for
degradation, thus reducing the availability of Wnt receptors
(28).
Bone Morphogenetic Proteins (BMPs). Except for BMP-1, all
these proteins belong to the TGF-β superfamily. Identification
of skeletal abnormalities in animals and patients with mutations
in the BMP genes has highlighted the role of these proteins in
bone metabolism (29-31). In vitro studies demonstrated that
treatment with BMPs enhances the expression of ALP,
parathyroid hormone related peptide (PTHrP) receptor type I,
collagen I and osteocalcin (32) and stimulated the formation of
mineralized bone-like nodules (33).
b) Osteoblast function
As already described, the principal function of the osteoblasts
is to synthesize the proteins of the bone matrix and to attend
the process of calcification. Indeed, several evidence reported
a crucial role of osteoblasts in osteoclast biology by expressing
and/or secreting key molecules that in turn regulate osteoclas-
togenesis and bone resorption (1). This latter issue will be
showed in detail in the next paragraphs.
Regulation and function of osteoclasts
Osteoclastogenesis
Osteoclasts, the cells devoted to resorb the bone matrix, arise
from the monocyte/macrophage lineage (34). They are multinu-
cleated cells (from four up to twenty nuclei) formed by the fu-
sion of mononuclear precursors (35). Starting from totipotent
heamatopoietic stem cells, the transcription factor PU.1, along
with the macrophage colony stimulating factor (M-CSF) drive
the commitment of a common progenitor for macrophages and
osteoclasts. In particular, M-CSF stimulates proliferation of os-
teoclast precursors and upregulates RANK expression, while
PU.1 positively regulates the transcription of c-Fms, the M-CSF
receptor (36). With the appearance of c-Fms and RANK recep-
tors, the precursors become fully committed to an osteoclast
lineage. RANKL pathway is mandatory for osteoclast differenti-
ation and function, although it is not the only player for a cor-
rect osteoclastogenesis, as described below. 
a) Osteoclast regulation
RANKL pathway. RANKL is a type II membrane protein be-
longing to the TNF superfamily, while its receptor RANK is a
type I membrane protein. Osteotropic hormones and factors
such as 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), PTH,
prostaglandin E2 (PGE2) and IL-11 up-regulate the expression
of RANKL on membrane surface of osteoblasts/stromal cells.
RANKL interacts with its receptor RANK, located on the pre-os-
teoclast surface, which in turn activates the signalling by re-
cruiting adaptor molecules belonging to the TNF-receptor asso-
ciated factors (TRAF) family (Figure 3A). Indeed, RANK cyto-
plasmic tail contains three binding sites for TRAF6 (37-39).
This interaction is mandatory for osteoclast differentiation, as
TRAF6 knock out mice develop osteopetrosis (40, 41). The
binding of TRAF6 to RANK induces the trimerization of TRAF6,
leading to the activation of the transcription factor nuclear fac-
tor kappaB (NF-κB) and of the mitogen-activated kinases
(MAPKs) (42) (Figure 3A).
NF-κB includes a family of dimeric transcription factors, which
reside in the cytoplasm in non-stimulated conditions. However,
they enter nucleus upon cell stimulation of various factors, in-
cluding RANKL (43, 44) and regulate transcription of several
genes. Among them, it has been demonstrated that NFkB up-
regulates the expression of another key molecule of osteoclast
differentiation, that is the nuclear factor of activated T cells, cy-
toplasmic 1 (NFATc1) transcription factor (45, 46). This initial
induction requires the interaction of NF-κB with NFATc2, which
is recruited to the NFATc1 promoter independently of RANKL
stimulation (47) (Figure 3A). 
Another crucial step for osteoclasts differentiation is the recruit-
ment of the transcription factor complex AP-1, which is com-
posed of the c-Fos, c-Jun and ATF proteins. In particular, c-
Fos is specifically induced by RANK and is critical for osteo-
Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 49-56 51
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clastogenesis, as knock out c-Fos mice develop osteopetrosis
due to the lack of osteoclasts (48). AP-1 activation along with a
calcium-signal further induces NFATc1 transcription, thus al-
lowing its autoamplification (47).
In cooperation with AP-1, PU.1, NF-κB and MITF, NFATc1 reg-
ulates the transcription of several target genes involved in os-
teoclast differentiation and function. Among them, cathespin K,
calcitonin receptor, tartrate-resistant acid phosphatase
(TRAcP) (49, 50), β3 integrin and osteoclast-associated recep-
tor (OSCAR) (51) (Figure 3B).
Osteoclast regulation by osteoblasts. The principal regulators of
osteoclastogenesis are the osteoblasts. Indeed, the RANKL/
RANK signalling relies on the cell-cell interaction between the os-
teoblasts and the osteoclast precursors. Another key molecule
secreted by osteoblasts which interfere with the RANKL pathway
is osteoprotegerin (OPG) a decoy receptor for RANKL (52),
which has an osteoprotective role. Indeed, OPG is a secreted
protein having the same structure of RANK so that it binds to
RANKL avoiding its interaction with RANK, with a consequent in-
hibition of osteoclastogenesis (Figure 3A). 
Osteoblasts trigger osteoclastogenesis also by expressing on
their membrane surface the M-CSF, which interacts with its re-
ceptor c-Fms present on osteoclast precursors thus stimulating
their proliferation and osteoclast differentiation (Figure 3A).
Osteoclast regulation by immune system. Several evidence
has indicated a tight relationship between the immune system
and bone, leading to a new interdisciplinary field, called os-
teoimmunology, focused to investigate the molecular mecha-
nisms shared by these two tissues (53-55). These findings also
point out that the RANKL pathway is necessary but not suffi-
cient to trigger osteoclast differentiation. As described in Figure
4, osteoblasts can regulate osteoclast differentiation by inter-
acting with immunoglobulin (Ig)-like receptors, such as the os-
teoclast-associated receptor (OSCAR), whose ligand has not
yet clearly identified. These receptors are associated with im-
munoreceptor tyrosine-based activation motif (ITAM)-harbour-
ing adaptor molecules DAP12 and Fc-receptor common γ-sub-
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Figure 3 - Schematization of the RANKL/RANK pathway. (A) RANKL
expressed on the membrane surface of osteoblasts (OBL) interacts
with RANK, expressed by pre-osteoclasts (OCL). This interaction re-
cruits TRAF6 that activates NFκB and c-Fos, the latter dimerizing with
c-Jun and forming the AP-1 complex. Both transcription factors cooper-
ate to trigger transcription of NFATc1, which in turn promote its autoam-
plification. (B) NFATc1, AP-1, PU.1 and MITF cooperate to induce oste-
clast genes transcription. 
Figure 4 - Schematization of the immunological interplay between osteoclasts and osteoblasts. Osteoblast (OBL) interacts whit Immunoglobulin-like
receptor (Ig-like receptor) expressed on pre-osteoclast (OCL) surface, thus allowing the phosphorylation of Dap12 or Fcrg and the subsequent activa-
tion of the calcium signalling, which potentiates autoamplification of NFATc1.
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unit (FcRg). The role of the latter molecules in osteoclast regu-
lation has been underlined by the evidence that mice deficient
in both DAP12 and FcRγ have an osteotropic phenotype (56,
57). Phosphorylation of the ITAM sequence in DAP12 or FcRγ,
resulting after RANK activation, allows the recruitment of
splenocyte tyrosine kinases (SYK) and the consequent activa-
tion of the phospholypase Cγ (PLCγ), which in turn triggers cal-
cium signalling. Calcium signalling promotes osteoclastogene-
sis by activating the CAMKIV (calcium/calmodulin-dependent
protein kinase type IV), which concurs to c-Fos activation, and
calcineurin, both cooperating to potentiate NFATc1 auto-ampli-
fication (53).
Inflammatory cytokines and osteoclastogenesis. Several find-
ings have demonstrated the involvement of some inflammatory
cytokines produced by macrophages, such as interleukin (IL)-
1, TNFα and IL-6, in osteoclast differentiation and function (58,
44) thus further supporting the tight relationship between bone
and immune system. 
TNFα is able to directly stimulate osteoclastogenesis in the
presence of M-CSF (59, 60) by stimulating the activation of NF-
κB mainly through TRAF2. Moreover, along with TGFβ it in-
duces in vitro osteoclastogenesis even in the absence of
RANK or TRAF6 (61).
IL-1 is not able alone to induce osteoclast differentiation, but it
synergizes with RANKL to induce osteoclastogenesis and bone
resorption, probably by stimulating TRAF6. Moreover, it indi-
rectly promotes osteoclastogenesis by stimulating osteoblast
secretion of PGE2 and RANKL (44).
Interferon-β (IFN-β) is another cytokine crucial in immune re-
sponse that negatively affects osteoclatogenesis. Indeed,
RANKL signalling induces IFN-β that in turn acts as a negative
feedback regulator by inhibiting cFos expression (62).
b) Osteoclast function
Once differentiated, multinucleated osteoclasts need to adhere
to the bone matrix and to polarize in order to resorb bone. In-
deed, two principal domains can be identified on the osteoclast
plasma membrane: the basolateral and the apical domains,
which also differ for their function. In the apical domain, it is
possible to identify a further membrane specialization, that is
the ruffled border, characterized by several folding of the mem-
brane and representing the resorbing organ (51). 
One of the earliest events of osteoclast activity is to degrade
the inorganic component of the bone matrix, that is the alkaline
salts of bone mineral hydroxyapatite. This can be obtained by
the release of propons into the area to be resorbed, called re-
sorption lacuna (63, 64). Furthermore, this function also re-
quires sealing the underlined bone matrix, which is obtained
through a cytoskeletal rearrangement and the subsequent for-
mation of the actin ring. This is a circumferential structure that
surrounds the ruffled membrane and isolates the acidified re-
sorptive microenvironment from the extracellular space. It is
formed by several dynamic and dot-like structures called po-
dosomes, each of them consisting of an actin core surrounded
by the αvβ3 integrin and associated cytoskeletal proteins such
as vinculin, α-actinin and talin (65, 66). 
As already told, the first step of bone resorption is the release
of protons in the compartment between the osteoclast and the
bone surface via an electrogenic proton pomp called vacuolar
type ATPase (67, 68), which is present both in intracellular
vesicles as well as in the ruffled border (67-69). This is a cru-
cial step, as demonstrated by the fact that mutations in the a3
subunit of vacuolar ATPase cause osteopetrosis in humans
(70, 71).
The production of protons is ensured by the activity of the car-
bonic anhydrase II (CA II) (72) which catalyses hydration of
CO2 thus forming carbonic acid (H2CO3). H2CO3 in turn dissoci-
ates to protons (H+) and bicarbonate ions (HCO3–). H+ are
then secreted in the resorption lacuna, while HCO3– are ex-
truded via an electroneutral chloride/bicarbonate exchanger in
the basolateral membrane (73). Moreover, the chloride ion
(Cl–) that enters the cell in exchange of HCO3- are transported
into the resorptive microenvironment through a chloride chan-
nel (74), thus generating HCl (75). The functional importance of
chloride channels was confirmed by the evidence that loss of
the chloride channel isoform CIC-7 leads to osteopetrosis in
human and mice (76). 
Dissolution of mineral crystals allows the digestion of the bone
matrix organic component that is performed by matrix metallo-
proteinases (MMPs) and lysosomial cathepsins. Among the lat-
ter, cathepsin K has a crucial role, as its deletion in mice leads
to osteopetrosis (77, 78), while mutations in cathepsin K gene
lead to pycnodysostosis (79, 80). As far as the MMPs is con-
cerned, osteoclasts mainly produce the MMP-9 isoform and to
a lesser extent the MMP-14 (81, 82).
Diseases associated to deregulation of osteoclasts
The correct balance between bone deposition and resorption is
crucial for the proper maintenance of the bone mass. More-
over, a complex network of pathways attends the regulation of
osteoclasts and osteoblasts activity, as demonstrated in the
above paragraphs. Among the bone pathologies, we will briefly
describe two opposite diseases, both due to an abnormal os-
teoclast function. These diseses also mirror the complexity of
the mechanisms involved in bone mass regulation. 
Rheumatoid arthritis
It is well known that this pathology is due to an inflammation of
the synovial membrane with a subsequent destruction of the
bone mediated by the osteoclasts (83). However the molecular
mechanisms that induce abnormal osteoclast activation have
only recently been clarified (53). Cells in the synovium include
macrophages, fibroblasts, dendritic cells, plasma cells and
most importantly, infiltrated CD4+ T cells, which are a hallmark
of the pathogenesis of arthritis (84, 85). Recent reports show
that among the latter cells a specific subset, the interleukin-17
(IL17)-producing T helper cells (TH17 cells) have a crucial role
in osteoclast activation (55). These cells do not produce IFNγ,
which has an anti osteoclastogenesis activity, while they se-
crete large amounts of IL-17 that stimulates the expression of
RANKL by synovial fibroblasts. IL-17 also acts on
macrophages by stimulating their secretion of inflammatory cy-
tokines including TNF, IL-1 and IL-6, which in turn trigger os-
teoclastogenesis and bone resorption directly or indirectly by
stimulating expression of RANKL. Finally, TH17 cells per se ex-
press RANKL (55,86).
Osteopetrosis
Osteopetrosis is a rare genetic disease characterized by an
increase of the bone mass due to an inability of osteoclasts to
resorb bone (87). According to the way of transmission and to
the clinical manifestations, it can be classified into three
forms with a wide range of severity: infantile malignant auto-
somal recessive osteopetrosis (ARO), intermediate autoso-
mal recessive osteopetrosis (IRO), and autosomal dominant
osteopetrosis (ADO). In the most severe forms, osteoclast
failure does not allows enlargement of bone cavities, thus im-
pairing development of bone marrow, leading to hematologi-
Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 49-56 53
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cal failure. Closure of bone foramina causes cranial nerve
compression with visual and hearing deterioration. Patients
also present with osteosclerosis, short stature, malformations
and brittle bones. This form is fatal in infancy, and is cured
with hematopoietic stem cell transplantation, with a rate of
success <50% and unsatisfactory rescue of growth and visual
deterioration (87).
Loss-of-function mutations of various genes involved in osteo-
clast function are responsible for this disease. Among them,
the TCIRG1 gene, which encode for the a3 subunit of the
H+ATPase and accounting for >50% of cases (70, 71), the
CLC7 (76, 88) and the OSTM1 genes, which have closely re-
lated function and account for approximately 10% of cases (89-
91). Further genes are implicated in rare forms with various
severities and association with other syndromes and, recently,
the RANKL gene was found to be mutated in a subset of pa-
tients lacking osteoclasts (92). Autosomal recessive osteopet-
rosis may also have intermediate severity, with a small number
of cases due to loss-of-function mutations of the CAII (93) or
the PLEKHM1 genes (94). Dominant negative mutations of the
CLC7 gene cause the so-called Albers-Schönberg disease
(95), which represents the most frequent and heterogeneous
form of osteopetrosis, ranging from asymptomatic to intermedi-
ate/severe, thus suggesting additional genetic/environmental
determinants affecting penetrance (96). 
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